Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Zhenglong Sun currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 action is assigned to 1 distinct examiner and is located in 1 distinct art unit. This reflects a highly specific area of focus for the current prosecution activity within the Biotechnology & Pharmaceuticals sector.
NOAKES, SUZANNE MARIE is the busiest examiner, handling 1 pending office action. This 1 action represents the total 1 pending office actions for the portfolio. Because there is only 1 distinct examiner and 1 distinct art unit, the 1 pending action is being reviewed by a single official. This matching count between the 1 distinct examiner and the pending workload indicates a centralized point of contact for the company.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOAKES, SUZANNE MARIE | 1 | 73.4% | +18.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19069321 | SERINE PROTEASE FOR SELECTIVELY DEGRADING MUCINS AND USE THEREOF | NOAKES, SUZANNE MARIE | 66d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19069321 | SERINE PROTEASE FOR SELECTIVELY DEGRADING MUCINS AND USE THEREOF | NOAKES, SUZANNE MARIE | 66d overdue |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19069321 | SERINE PROTEASE FOR SELECTIVELY DEGRADING MUCINS AND USE THEREOF | NOAKES, SUZANNE MARIE | 1656 | §102§112 | Non-Final OA | 66d overdue | Pending | Mar 04, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZhenglong Sun has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Suzanne Marie Noakes has the most, with 1 of Zhenglong Sun's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
